The 70-Gene Signature (MammaPrint): A Prognostic Genomic Classifier in Early-Stage Breast Cancer

Introduction

Among the genomic tools that have reshaped how pathologists and oncologists estimate outcome in early breast cancer, the 70-gene signature—marketed as MammaPrint—occupies an important place. It is a prognostic assay: its purpose is to estimate the risk of distant recurrence, and in doing so, to help clarify which patients derive meaningful benefit from adding chemotherapy to their treatment plan. This article explains, in educational terms, what the test measures, how it is performed and interpreted, and what its results do—and do not—determine.

What the Test Measures

The 70-gene signature interrogates the expression levels of a defined panel of 70 genes drawn from biological pathways relevant to tumor behavior, including proliferation, invasion, metastasis, and angiogenesis. Rather than examining a single protein or mutation, the assay captures a coordinated pattern of gene activity within the tumor. The underlying premise is that aggressive tumors "speak" through their transcriptome: the collective up- or down-regulation of these genes correlates with the biological propensity to spread beyond the breast.

The output is deliberately simple. The complex expression data are reduced by an algorithm into a single binary classification—low genomic risk or high genomic risk—reflecting the estimated likelihood of distant metastasis over the years following diagnosis.

How It Is Tested

The assay is a multigene expression signature performed on microarray or next-generation sequencing platforms. A notable practical strength is specimen flexibility: it can be run on fresh tissue or formalin-fixed, paraffin-embedded (FFPE) material, the latter being the everyday product of routine surgical pathology.

As with any expression-based test, results depend on adequate tumor content and preservation of RNA quality. Preanalytic variables—ischemia time before fixation, fixation duration, and the age and handling of paraffin blocks—can affect RNA integrity, and laboratories require samples that meet minimum tumor-cellularity and quality thresholds. Pathologist involvement in selecting and annotating a representative tumor block is therefore an essential upstream step, even though the downstream computation is automated.

The scoring is intentionally binary. Unlike continuous-score assays that yield an intermediate zone, the 70-gene signature partitions patients into two categories, low or high genomic risk. This dichotomy is a defining feature of how the test is used in clinical decision-making.

What Each Result State Means

• Low genomic risk: The tumor's expression pattern predicts a comparatively favorable outcome, with a lower estimated probability of distant recurrence. This result identifies patients whose biology suggests limited additional benefit from chemotherapy.

• High genomic risk: The expression pattern predicts a less favorable outcome, with a higher estimated probability of distant recurrence. This result flags a tumor whose biology is more aggressive.

It is important to frame these as probabilistic estimates of tumor behavior, not certainties about an individual's future. The signature describes the biology of the tumor; it does not, on its own, dictate a treatment.

What It Determines for Treatment Eligibility

The pivotal evidence comes from the MINDACT trial, a prospective randomized study [1]. MINDACT specifically examined patients who were classified as clinically high risk by traditional clinicopathologic criteria (such as tumor size, grade, and nodal status) but as low genomic risk by the 70-gene signature—a group with discordant risk assessments. Among these patients, largely those with hormone-receptor–positive, HER2-negative disease, the trial evaluated whether the genomic result could safely guide the decision to omit chemotherapy [1].

The evidence from MINDACT suggests that patients who are clinically high risk but genomically low risk have a favorable distant metastasis–free outcome, and that the absolute benefit of adding chemotherapy in this discordant group is small [1]. In educational terms, the test therefore helps identify a subset of clinically high-risk HR+/HER2- patients for whom chemotherapy may reasonably be forgone.

Framed appropriately, the assay informs eligibility for consideration of cytotoxic chemotherapy—it helps distinguish patients whose tumor biology argues for that drug class from those in whom it may add little. It does not prescribe a specific regimen, nor does it determine endocrine therapy decisions, which rest on receptor status. This is a tool that refines a shared decision between patient and clinician; it is not a directive.

Caveats and What Is Evolving

Several important qualifications belong in any careful reading of this test.

First, the strongest validated application is in the HR+/HER2- population with clinically high-risk features, as studied in MINDACT [1]. Extrapolating the result to other biological subtypes should be done with caution, recognizing the boundaries of the trial evidence.

Second, the binary cutoff is both a strength and a limitation. It offers clarity but collapses a continuous biological spectrum into two bins; tumors near the threshold may warrant particularly thoughtful interpretation in the context of all other clinical information.

Third, the definition of HER2-negative is itself in flux. The emergence of the "HER2-low" category—tumors with low-level HER2 protein expression that were historically grouped as HER2-negative—raises open questions about how such cases behave and how genomic classifiers apply to them. This is a fast-moving area, and the evidence base for integrating HER2-low status with the 70-gene signature is still maturing. Readers should regard cutoffs and subgroup boundaries in this space as contested and evolving.

Finally, genomic risk is one input among several. Nodal status, tumor size, patient age, comorbidities, and patient values all remain integral to decision-making. The 70-gene signature adds resolution to the biological question of recurrence risk; it does not replace clinical judgment.

Summary

The 70-gene signature is a prognostic, binary genomic classifier applicable to fresh or FFPE tumor tissue, dividing patients into low or high genomic risk. Its best-validated role, supported by MINDACT, is helping identify clinically high-risk HR+/HER2- patients for whom the added benefit of chemotherapy may be limited [1]. Used as an educational and decision-support tool—never as a standalone command—it exemplifies how molecular pathology can sharpen, without supplanting, individualized clinical reasoning.

References

1. Cardoso F, van't Veer LJ, Bogaerts J, et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016. doi:10.1056/NEJMoa1602253.